

REMARKS/ARGUMENTS

Reconsideration of this application and entry of the foregoing amendments are respectfully requested.

The Abstract has been revised so as to include the subject matter of the pending claims.

Claim 44 has been revised to define the invention with additional clarity. The claim as presented is fully supported by an enabling disclosure. Claims 60 and 61 have been revised so as to be placed in independent form.

Claim 61 stands rejected under 35 USC 101. Withdrawal of the rejection is requested in view of the above-noted revision of that claim. Reconsideration is requested.

Claims 44, 60 and 61 stand rejected under 35 USC 112, second paragraph, as allegedly being indefinite. Withdrawal of the rejection is requested in view of the above-noted claim revisions. Reconsideration is requested

Claims 43-61 stand rejected as allegedly representing obviousness type double patenting over claims of Appln. No. 12/063,920 and claims of Appln. No. 12/184,473. Given the provisional nature of the rejections, it is requested that they be held in abeyance until the case is otherwise in condition for allowance. The possibility of filing Terminal Disclaimers is noted.

On page 5 of the Action, the Examiner contends that claims 43-61 of this application conflict with claims 22-25 of Appln. No. 12/184,473. Applicants respectfully disagree.

Claims 22-25 of Appln. No. 12/184,473 are directed to a method of screening an antibiotic compound..... (claim 22). The remaining claims are dependant on this method claim. Claims 43 to 61 of the present application are drawn to a method of identifying a candidate therapeutic agent that comprises contacting a membrane comprising a G-protein coupled

MEUTERMANS et al
Appl. No. 10/530,851
October 8, 2010

receptor (GPCR) with a candidate compound of Formula I. Bacteria, which are the targets of antibiotics, are prokaryotic cells. Prokaryotic cells do not have GPCR's. GPCR's are exclusive to eukaryotes. Thus, no conflict is seen.

As regards claims 1-20 of Appln. No. 12/063,920, the Examiner's comments regarding the need to maintain a line of demarcation between the applications are noted.

This application is submitted to be in condition for allowance and a Notice to that effect is requested.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: Mary J. Wilson
Mary J. Wilson
Reg. No. 32,955

MJW:tat
901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100